-
A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
This is a study testing MOMA-313, a drug that blocks a protein called DNA polymerase theta (Pol?) for prostate cancer with a genetic feature called ...
Phase
Interventional
-
Phase 1 Dose-Escalation Study of KTX-2001 (an NSD2 Inhibitor) Alone and in Combination with Darolutamide for Metastatic Castration-Resistant Prostate Cancer
This is a multicenter, open-label Phase 1 study in participants with metastatic castration-resistant prostate cancer (mCRPC) to investigate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and ...Phase
Interventional
-
A PHASE 1 OPEN-LABEL MULTICENTER STUDY OF JANX007 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
This study is a first-in-human (FIH), Phase 1, open-label, multicenter study to assess the safety, tolerability, PK, PD, and preliminary efficacy of JANX007 administered as ...Phase
Interventional
